Exploring the potential of vamotinib in Ph+ leukemias: is it indeed a 3rd generation tyrosine kinase-inhibitor?
The development of tyrosine kinase inhibitors (TKIs) has markedly improved outcomes in Philadelphia chromosome–positive leukemias; however, resistance mediated by BCR::ABL1 kinase domain (KD) mutations remains a major challenge. While the third-generation TKIs ponatinib and asciminib can suppress many resistant mutatio...